Onco-Innovations Announces Initiation of Research Collaboration within PROmAI

• Date: 2026-05-12
• Headline: Onco-Innovations Announces Initiation of Research Collaboration within PROmAI
• Partner: AstraZeneca via subsidiary Inka Health Corp.
• Program: PROmAI (Predicting Oncology Outcomes using Multimodal Artificial Intelligence)
• Focus: Development of AI-based approaches to improve prediction of clinical outcomes using multimodal datasets (molecular, clinical, imaging).
• Objective: Strengthen decision support tools for translational research and clinical development strategy.
• Context: Follows previous AI collaborations with OneMedNet (April 2026) and Kuano (November 2025).

• Strategic Validation: The partnership with AstraZeneca validates the company's AI-driven oncology thesis, moving beyond smaller partners like OneMedNet or Kuano.
• Financial Impact: No immediate revenue or capital infusion is disclosed in this release; it is a research collaboration.
• Market Context: The stock has declined over 98% from its May 2025 highs ($39.53) to current levels ($0.41). Recent private placements occurred at $0.65 (March 2026), meaning the current price is significantly below recent institutional entry points.
• Catalyst Status: While positive, this news aligns with a pattern of AI partnerships announced throughout 2025 and early 2026. It does not represent a sudden strategic pivot or M&A event that would qualify as "Game Changer."
• Risk Mitigation: The collaboration helps de-risk the AI component but does not address the immediate clinical risk of the PNKP Inhibitor (ONC010) or the company's cash burn rate.

• Company: Onco-Innovations Limited.
• Flagship Project: PNKP Inhibitor Technology (Drug Candidate ONC010).
• Mechanism: DNA Damage Response Inhibitor encapsulated in a proprietary nanoparticle micelle for tumor-targeted delivery.
• AI Component: PROmAI program and SynoGraph AI model for evidence generation and patient identification.
• Development Stage: Preclinical transitioning to IND-enabling studies (Phase 1 readiness).
• Key Partners: Dalton Pharma Services (Manufacturing), Nucro-Technics (Bioanalysis), AstraZeneca, OneMedNet, Kuano.